ABIVAX Société Anonyme – LSE:0RA9.L
ABIVAX Société Anonyme stock price today
ABIVAX Société Anonyme stock price monthly change
ABIVAX Société Anonyme stock price quarterly change
ABIVAX Société Anonyme stock price yearly change
ABIVAX Société Anonyme key metrics
Market Cap | 469.32M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -7 |
Revenue | 8.96M |
EBITDA | -187.86M |
Income | -217.58M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -2094.6% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeABIVAX Société Anonyme stock price history
ABIVAX Société Anonyme stock forecast
ABIVAX Société Anonyme financial statements
| Jun 2022 | 2.22M | -29.55M | -1326.44% |
|---|---|---|---|
| Dec 2022 | 2.24M | -40.29M | -1792.39% |
| Jun 2023 | 2.24M | -51.95M | -2311.08% |
| Dec 2023 | 2.24M | -95.78M | -4266.68% |
| 2025 | 3.09M | -114.72M | -3704.17% |
|---|---|---|---|
| 2026 | 4.57M | -113.00M | -2470.62% |
| 2027 | 78.38M | -106.22M | -135.52% |
| 2028 | 273.74M | -43.92M | -16.05% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 75544000 | 68.35M | 90.48% |
|---|---|---|---|
| Dec 2022 | 75544000 | 68.35M | 90.48% |
| Jun 2023 | 171100000 | 90.59M | 52.95% |
| Dec 2023 | 327062000 | 131.05M | 40.07% |
| Jun 2022 | -25.75M | -3.77M | -4.60M |
|---|---|---|---|
| Dec 2022 | -39.82M | 44K | 40.15M |
| Jun 2023 | -28.84M | -1.71M | 117.99M |
| Dec 2023 | -71.16M | -8.78M | 222.57M |
ABIVAX Société Anonyme alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 26 |
| Dec 2023 | 26 |
| Jan 2024 | 26 |
| Feb 2024 | 26 |
| Mar 2024 | 26 |
| Apr 2024 | 26 |
| May 2024 | 61 |
| Jun 2024 | 61 |
| Jul 2024 | 61 |
ABIVAX Société Anonyme other data
| Insider | Compensation |
|---|---|
Prof. Hartmut J. Ehrlich Chief Executive Officer | $410,580 |
Mr. Didier Blondel Vice President, Admin. & Financial Director and Sec. of the Board of Directors | |
Ms. Raquel Lizarraga Investor Relations Mang. | |
Ms. Regina Jehle Director of Communication | |
Anne Pascard HR Mang. | |
Mr. Pierre Courteille M.B.A. Chief Commercial Officer & Vice President of Bus. Devel. | |
Dr. Jean-Marc Steens M.D. Vice President & Chief Medical Officer | |
Dr. Alexandra Pearce Vice President of Regulatory Affairs, Quality & Pharmaco-Vigilance | |
Dr. Philippe Pouletty Founder & Chairman | |
Mr. Alain Chevallier Senior Advisor |
-
What's the price of ABIVAX Société Anonyme stock today?
One share of ABIVAX Société Anonyme stock can currently be purchased for approximately $28.4.
-
When is ABIVAX Société Anonyme's next earnings date?
Unfortunately, ABIVAX Société Anonyme's (0RA9.L) next earnings date is currently unknown.
-
Does ABIVAX Société Anonyme pay dividends?
No, ABIVAX Société Anonyme does not pay dividends.
-
How much money does ABIVAX Société Anonyme make?
ABIVAX Société Anonyme has a market capitalization of 469.32M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 0.83% to 4.62M US dollars.
-
What is ABIVAX Société Anonyme's stock symbol?
ABIVAX Société Anonyme is traded on the LSE under the ticker symbol "0RA9.L".
-
What is ABIVAX Société Anonyme's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of ABIVAX Société Anonyme?
Shares of ABIVAX Société Anonyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ABIVAX Société Anonyme's key executives?
ABIVAX Société Anonyme's management team includes the following people:
- Prof. Hartmut J. Ehrlich Chief Executive Officer()
- Mr. Didier Blondel Vice President, Admin. & Financial Director and Sec. of the Board of Directors
- Ms. Raquel Lizarraga Investor Relations Mang.
- Ms. Regina Jehle Director of Communication
- Anne Pascard HR Mang.
- Mr. Pierre Courteille M.B.A. Chief Commercial Officer & Vice President of Bus. Devel.
- Dr. Jean-Marc Steens M.D. Vice President & Chief Medical Officer
- Dr. Alexandra Pearce Vice President of Regulatory Affairs, Quality & Pharmaco-Vigilance
- Dr. Philippe Pouletty Founder & Chairman
- Mr. Alain Chevallier Senior Advisor
-
Is ABIVAX Société Anonyme founder-led company?
Yes, ABIVAX Société Anonyme is a company led by its founder Dr. Philippe Pouletty.
-
How many employees does ABIVAX Société Anonyme have?
As Jul 2024, ABIVAX Société Anonyme employs 61 workers, which is 135% more then previous quarter.
-
When ABIVAX Société Anonyme went public?
ABIVAX Société Anonyme is publicly traded company for more then 8 years since IPO on 30 Sep 2016.
-
What is ABIVAX Société Anonyme's official website?
The official website for ABIVAX Société Anonyme is abivax.com.
-
How can i contact ABIVAX Société Anonyme?
ABIVAX Société Anonyme can be reached via phone at +33 1 53 83 08 41.
ABIVAX Société Anonyme company profile:
ABIVAX Société Anonyme
abivax.comLSE
62
Medical - Pharmaceuticals
Healthcare
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Paris, 75008
:
ISIN: FR0012333284
:
